Cookies on VetMed Resource

Like most websites we use cookies. This is to ensure that we give you the best experience possible.

 

Continuing to use www.cabi.org  means you agree to our use of cookies. If you would like to, you can learn more about the cookies we use.

VetMed Resource

Veterinary information to support practice, based on evidence and continuing education

Sign up to start receiving our Veterinary & Animal Sciences e-newsletter, book alerts and offers direct to your inbox.

Results per page:

Search results

Abstract

The aims of this study were to report treatment outcomes for dogs with histiocytic sarcoma (HS) treated with both lomustine and epirubicin, and to report response rates to epirubicin as a rescue therapy in dogs previously treated with lomustine. Medical records of dogs with a diagnosis of HS that...

Author(s)
Mason, S. L.; Finotello, R.; Blackwood, L.
Publisher
Wiley, Oxford, UK
Citation
Veterinary and Comparative Oncology, 2018, 16, 1, pp E30-E37
AbstractFull Text

Background: Canine lymphoma is one of the most frequently occurring malignant neoplasms in dogs. Anthracycline-based chemotherapy for the treatment of canine lymphoma is very effective; however, there is not enough evidence for the development of cardiac toxicity using several anthracyclines as...

Author(s)
Tagawa, M.; Shimbo, G.; Uemura, A.; Matsumoto, K.
Publisher
Faculty of Veterinary Medicine, University of Tripoli, Tripoli, Libya
Citation
Open Veterinary Journal, 2021, 11, 1, pp 6-10
Abstract

Objective: Cytarabine, a cell-cycle phase-specific antimetabolite, has been reported to improve outcomes in dogs with bone marrow (BM) or central nervous system (CNS) lymphoma involvement receiving combination chemotherapy. The objective of this study was to evaluate the incidence and severity of...

Author(s)
Guillen, A.; Finotello, R.; Harper, A.; Killick, D.; Amores-Fuster, I.; Blackwood, L.
Publisher
Wiley, Melbourne, Australia
Citation
Australian Veterinary Journal, 2020, 98, 3, pp 69-78
Abstract

Objective - To determine the efficacy and toxic effects of epirubicin for the adjuvant treatment of dogs with splenic hemangiosarcoma and identify prognostic factors. Design - Retrospective case series. Animals - 59 client-owned dogs that underwent splenectomy for splenic hemangiosarcoma treated...

Author(s)
Kim, S. E.; Liptak, J. M.; Gall, T. T.; Monteith, G. J.; Woods, J. P.
Publisher
American Veterinary Medical Association, Schaumburg, USA
Citation
Journal of the American Veterinary Medical Association, 2007, 231, 10, pp 1550-1557
Abstract

The aim of the study was to report the outcome of treatment of 97 dogs with lymphoma that received a multi-agent chemotherapy protocol containing epirubicin as the primary anthracycline. Seventy-five dogs received a 25-week protocol with no maintenance phase whilst 22 dogs received a maintenance...

Author(s)
Elliott, J. W.; Cripps, P.; Marrington, A. M.; Grant, I. A.; Blackwood, L.
Publisher
Wiley-Blackwell, Oxford, UK
Citation
Veterinary and Comparative Oncology, 2013, 11, 3, pp 185-198
Abstract

The DMAC protocol (dexamethasone, melphalan, actinomycin-D, cytarabine) has been evaluated in American studies for the treatment of relapsed canine lymphoma, comparing similarly to other rescue protocols. The aim of this study was to evaluate efficacy and toxicity of DMAC, in a larger UK cohort of...

Author(s)
Smallwood, K.; Tanis, J. B.; Grant, I. A.; Blackwood, L.; Killick, D. R.; Amores-Fuster, I.; Elliott, J.; Mas, A.; Harper, A.; Marrington, M.; Finotello, R.
Publisher
Wiley, Oxford, UK
Citation
Veterinary and Comparative Oncology, 2019, 17, 2, pp 165-173
Abstract

Multi-agent chemotherapy (vincristine, epirubicin and prednisolone) including either cyclophosphamide (CEOP) or lomustine (LEOP) was given as first-line chemotherapy to treatment-naïve canine lymphoma patients with measurable, high grade T-cell lymphoma (HGTCL). All patients responded to either...

Author(s)
Elliott, J.; Baines, S.
Publisher
Wiley, Melbourne, Australia
Citation
Australian Veterinary Journal, 2019, 97, 9, pp 308-315
Abstract

An 8-year-old American cocker spaniel dog was diagnosed with dilated cardiomyopathy. Four years earlier, the dog had been diagnosed with multicentric lymphoma and had received 4 cycles of multi-agent chemotherapy, including doxorubicin and epirubicin. The total cumulative dose of epirubicin was 168 ...

Author(s)
Lee YeRin; Kang MinHee; Park HeeMyung
Publisher
Canadian Veterinary Medical Association, Ottawa, Canada
Citation
Canadian Veterinary Journal, 2015, 56, 6, pp 571-574
AbstractFull Text

Anthracyclines are anticancer drugs, most commonly used for therapy of canine malignant mammary tumours. It is known that anthracyclines cause cardiotoxicity, partly due to their interaction with iron. Iron overload potentiates the cardiotoxicity of the antracyclines. Desferioxamine (Desferal) is a ...

Author(s)
Todorova, I.
Publisher
University "Ss Cyril and Methodius" in Skopje, Faculty of Veterinary Medicine in Skopje, Skopje, Republic of Macedonia
Citation
Book of Proceedings, Days of Veterinary Medicine 2012, 3rd International Scientific Meeting, Macedonia, 2-4 September 2012, 2012, pp 52-55
Abstract

The standard of care treatment for canine lymphoma is multi-agent chemotherapy containing prednisolone, cyclophosphamide, vincristine and an anthracycline such as doxorubicin (CHOP) or epirubicin (CEOP). Lomustine, vincristine, procarbazine, and prednisone (LOPP) has been evaluated as a rescue,...

Author(s)
Tanis, J. B.; Mason, S. L.; Maddox, T. W.; Blackwood, L.; Killick, D. R.; Amores-Fuster, I.; Harper, A.; Finotello, R.
Publisher
Wiley, Oxford, UK
Citation
Veterinary and Comparative Oncology, 2018, 16, 3, pp 361-369

Refine Results

Sort Order
Author
Geographical Location
Item Type
Language
Organisms
Subject Topics